Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) has been approved for gastric ulcer and reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients.

• Azurity Pharmaceuticals, Inc. has received FDA approval for the use of Konvomep, an oral liquid formulation of the FDA-approved proton pump inhibitor omeprazole and sodium bicarbonate combination
• It is expected that Konvomep™ will become commercially available in pharmacies nationwide in Q1 2023.

For full prescribing and additional information, please go to www.konvomep.com